Device Trial Radar · NCT07939620
Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
186
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
Jan 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Dr. August Wolff GmbH & Co. KG ArzneimittelNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Kosmoscience Ciência e Tecnologia Cosmética Ltda
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes. A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days. The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups. Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.
Conditions
- Dentin Hypersensitivity
Interventions
Toothpaste Containing 20% Hydroxyapatite and 2% Calcium HypophosphiteOther
Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.
Stannous Fluoride ToothpasteDevice
Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.
8% Arginine ToothpasteDevice
Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56Time frame: Baseline (Day 1) to Day 56 (±3 Days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kosmoscience
São Paulo, Valinhos, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.